Home » Topics » BioWorld Science

BioWorld Science
RSS

JD Bioscience presents 5-HT2A receptor antagonists

May 21, 2021

New DHODH inhibitors synthesized by Janssen

May 21, 2021

Biogen identifies BTK inhibitors

May 21, 2021

First patients dosed in phase I study of PBI-100

May 21, 2021

Corbus Pharmaceuticals divulges cannabinoid CB2 receptor agonists

May 21, 2021

C4 Therapeutics and Roche patent new PROTACs

May 21, 2021

KIF13B linked to progression of wet age-related macular degeneration

May 21, 2021

In vivo model developed for evaluating the cytokine release toxicity of bispecific antibodies

May 21, 2021

Avidity advances preclinical programs in DMD and myotonic dystrophy type 1

May 21, 2021

Olix initiates phase II study of OLX-10010 as treatment of hypertrophic scars

May 21, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.